Pacylex Presents Updates on the Journey of PCLX-001 to the Clinic at thewhig.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thewhig.com Daily Mail and Mail on Sunday newspapers.
Edmonton, Alberta and Austin, Texas (Newsfile Corp. - June 2, 2021) - To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Clinical site preparations
Photo Supplied by Alberta Cancer Foundation
Article continues below advertisement ↴
The Alberta Cancer Foundation is excited to announce a brand-new flagship cycling event taking place August 28, 2021.
The Enbridge Tour Alberta for Cancer will be the most “Alberta” cycling challenge this province has ever seen. With a route extending from Lethbridge to Fort McMurray, the Tour will keep the impact close to home raising funds in support of cancer research and care delivered by Albertans, for Albertans.
Over the past 12 years, Albertans have come together every summer to participate in an epic cycling challenge, raising millions of dollars in support of incredible cancer research and care. This brand-new event has a fresh name, but the goals and experience will remain the same as years past an inspiring cycling challenge that has an unparalleled impact on cancer outcomes for Albertans. Last year’s event raised 1.9 million dollars with over two thousand
Micorscope is used by researcher who use her hands holding and adjusting while science research in laboratory
Researchers at University of Alberta have uncovered a link between the expression of the protein galectin-9 (gal-9) and whether a cancer patient will benefit from immunotherapy.
The discovery could help inform physicians about which patients will likely respond to immunotherapy, and lead to better treatment options.
Shokrollah Elahi, a member of the Cancer Research Institute of Northern Alberta (CRINA), collaborated with oncology professor John Walker on Phase 2 clinical trial that examined 40 patients with virus-associated solid tumours (VASTs) who were put on immunotherapy.
They found there was a direct link between patients with high levels of gal-9 and those who had a poor prognosis and did not respond to immunotherapy. Further, patients with lower levels of gal-9 responded better to treatment.
A research group from the University of Alberta has identified a new approach to use 3D bioprinting technology to make custom-shaped cartilage that can be used in surgical procedures.